Showing 3221-3230 of 3448 results for "".
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e
- Environmental Groups Sue FDA to Take Formaldehyde Out of Salonshttps://practicaldermatology.com/news/environmental-groups-sue-fda-to-take-formaldehyde-out-of-salons/2458096/The Environmental Working Group (EWG) and Women’s Voices for the Earth (WVE) are suing the Food and Drug Administration (FDA) because of the group’s failure to act on dangerous hair straighteners that contain unsafe levels of formaldehyde and pose a significant health hazard to consum
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Patent Challenge Filed for Generic Version Of Soolantra Creamhttps://practicaldermatology.com/news/patent-challenge-filed-for-generic-version-of-soolantra-cream/2458120/Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a
- Samsung Biologics to Manufacture Sun Pharma's Tildrakizumab for Psoriasishttps://practicaldermatology.com/news/samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis/2458130/Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Admi
- Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanomahttps://practicaldermatology.com/news/array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma/2458131/Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with&nbs